New Antibody-Vaccine combo aims to shield infants from malaria
NCT ID NCT06461026
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 33 times
Summary
This study tests whether giving infants an investigational antibody (L9LS) before a malaria vaccine (R21/Matrix-M) is safe and helps the vaccine work better. About 180 healthy infants in Mali, aged 1 to 12 months, will receive either the antibody or a placebo, followed by the vaccine. The goal is to find a new way to protect young children from malaria.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Faladje MRTC Clinic
Faladié, Koulikoro, Mali
-
Kalifabougou MRTC Clinic
Kalifabougou, Koulikoro, Mali
-
Torodo MRTC Clinic
Torodo, Koulikoro, Mali
Conditions
Explore the condition pages connected to this study.